225Ac-DOTA-M5A

N/A

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug Name225Ac-DOTA-M5A
Drug Alias Name225Ac-DOTA-M5A
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionAnti-CEA
TargetsCarcinoembryonic antigen
Therapy Area/IndicationsNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A